Literature DB >> 2960890

Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.

B Perussia1, C Ramoni, I Anegon, M C Cuturi, J Faust, G Trinchieri.   

Abstract

In this report, we show that in vitro stimulation of human peripheral blood mononuclear cells (PBMC) with B lymphoblastoid cell lines results in preferential proliferation of cells with the phenotypic, genotypic and functional characteristics of natural killer (NK) cells. This culture system offers a useful method for obtaining large numbers of pure NK cells on which biochemical, molecular and functional studies can be performed. Using this culture system, and average 25-fold increase in NK cell number is obtained, whereas the number of T cells is increased only 3-fold. At early times, activation of both T and NK cells occurs, as detected by the presence of activation antigens on both cell types, but actual proliferation of NK cells starts on day 6 of culture. Elimination of CD3(+)/CD5(+) T cells from the cultured cells gives homogeneous preparations of large numbers of CD16(+)/NKH-1(+) cells that have the morphology of large granular lymphocytes, are powerful effectors of both spontaneous and antibody-dependent cell-mediated cytotoxicity, and rapidly proliferate in the presence of recombinant interleukin 2 (rIL-2). As fresh NK cells, NK cell-enriched preparations from 10-day cultures of Daudi-stimulated PBMC do not show rearrangement of the gene for the beta-chain of the T cell antigen receptor; the 1.3-kb functional transcript of the beta-chain gene was not expressed in NK cells, but the 1.0-kb truncated transcript was present in all preparations. Our data indicate that proliferation of both T and NK cells is dependent upon IL-2 production in the culture, because an anti-IL-2 antiserum completely suppresses proliferation. Because T cells, and in particular CD4(+) T cells, are required for preferential proliferation of NK cells, the NK cell stimulation induced by the B cell line is probably in part indirect, and due to induction of IL-2 production by allogeneic stimulation of CD4(+) cells. However, the B cell lines also need to interact directly with NK cells because neither allogeneic PBMC nor high doses of rIL-2 are sufficient to induce preferential proliferation of NK cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960890

Source DB:  PubMed          Journal:  Nat Immun Cell Growth Regul        ISSN: 0254-7600


  74 in total

1.  Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement.

Authors:  R Paolini; R Molfetta; M Piccoli; L Frati; A Santoni
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

2.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

3.  Double-stranded RNA unwinding and modifying activity is detected ubiquitously in primary tissues and cell lines.

Authors:  R W Wagner; C Yoo; L Wrabetz; J Kamholz; J Buchhalter; N F Hassan; K Khalili; S U Kim; B Perussia; F A McMorris
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

4.  Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients.

Authors:  R Giacomelli; A Passacantando; G Frieri; I Parzanese; S D'Alò; P Vernia; M T Pimpo; C Petrucci; R Caprilli; M G Cifone; G Tonietti
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

5.  Expression and functional activity of the very late activation antigen-4 molecule on human natural killer cells in different states of activation.

Authors:  C Macías; J M Ballester; P Hernández
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

6.  A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Authors:  Giovanni F Torelli; Carmela Rozera; Laura Santodonato; Nadia Peragine; Giuseppina D'agostino; Enrica Montefiore; Maria R Napolitano; Domenica M Monque; Davide Carlei; Paola Mariglia; Simona Pauselli; Maria Gozzer; Mahnaz Shafii Bafti; Gabriella Girelli; Anna Guarini; Filippo Belardelli; Robin Foà
Journal:  Blood Transfus       Date:  2015-01-30       Impact factor: 3.443

7.  Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans.

Authors:  G Arancia; A Molinari; P Crateri; A Stringaro; C Ramoni; M L Dupuis; M J Gomez; A Torosantucci; A Cassone
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

Authors:  Natalia Lapteva; April G Durett; Jiali Sun; Lisa A Rollins; Leslie L Huye; Jian Fang; Varada Dandekar; Zhuyong Mei; Kimberley Jackson; Juan Vera; Jun Ando; Minhtran C Ngo; Elaine Coustan-Smith; Dario Campana; Susann Szmania; Tarun Garg; Amberly Moreno-Bost; Frits Vanrhee; Adrian P Gee; Cliona M Rooney
Journal:  Cytotherapy       Date:  2012-08-17       Impact factor: 5.414

9.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Authors:  Anna Kruschinski; Andreas Moosmann; Isabel Poschke; Håkan Norell; Markus Chmielewski; Barbara Seliger; Rolf Kiessling; Thomas Blankenstein; Hinrich Abken; Jehad Charo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

10.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

Authors:  Hiroyuki Fujisaki; Harumi Kakuda; Noriko Shimasaki; Chihaya Imai; Jing Ma; Timothy Lockey; Paul Eldridge; Wing H Leung; Dario Campana
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.